

Aspira Pathlab & Diagnostics Limited (Formerly known as Utkal Soap Products Ltd.) Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086 CIN:LB5 100MH1 973PLC289209 Corporate Office: Plot No. 6, RPT House, Sector 24, Turbhe, Navi Mumbai 400 703

September 05, 2018

BSE Limited Department of Corporate Services, Ground Floor, P. J. Towers, Dalal Street, Fort, Mumbai – 400 001.

Scrip Code: 540788

Sub:- Notice of 45th Annual General Meeting to be held on September 29, 2018

Dear Sir/Madam,


This is to inform you that the 45th Annual General Meeting of the members of the Company will be held on Saturday, 29th September, 2018 at 11.00 a.m. 608, Marathon Max, Mulund Goregaon Link Road, Mulund (West), Mumbai – 400080 (Maharashtra).

Please find enclosed herewith Notice of 45th Annual General Meeting of the Company.

Kindly take the same on record.

Thanking You,

For Aspira Pathlab & Diagnostics Ltd (Formerly known as Utkal Soap Products Limited)



NOTICE

NOTICE IS HEREBY GIVEN THAT THE 45th ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED (FORMERLY KNOWN AS UTKAL SOAP PRODUCTS LIMITED) ("COMPANY") WILL BE HELD ON SATURDAY, SEPTEMBER 29, 2018 AT 11.00 A.M AT 608, MARATHON MAX, MULUND GOREGAON LINK ROAD, MULUND (WEST), MUMBAI – 400080 (MAHARASHTRA) TO TRANSACT THE FOLLOWING BUSINESS.

ORDINARY BUSINESS

- 1. To receive, consider and adopt audited financial statements of the Company for the financial year ended **March 31, 2018** together with the reports of the Board of Directors and Auditors thereon.
- 2. To appoint a Director in place of Mr. Arvind Bhanushali, Director of the Company, who retires by rotation at this Annual General Meeting, and being eligible, offers himself for re- appointment.
- 3. To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 139 (1) and applicable provisions, if any, of the Companies Act, 2013 and rules, circulars, notifications made/issued there under, including any amendments, modification, variation or reenactment thereof, and in partial modification of resolution passed by the members of the Company at the 41st Annual General Meeting of the Company held on September 26, 2014, the appointment of **M/s. P Khetan & Co. Chartered Accountant**, Kolkata, bearing Membership No. 066080 and Firm Reg. No. – 327386E as the Statutory Auditors of the Company, for a term of Five Years, i.e. from the conclusion of 41stAnnual General Meeting till the conclusion of 46th Annual general meeting of the Company to be held in the year 2019 be and is hereby ratified at the remuneration of Rs. 2,50,000/ - for the said period in addition to reimbursement of actual out of pocket expenses as may be incurred by them in the performance of their duties"

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, desirable and expedient for giving effect to this resolution and/or otherwise considered by them to be in the best interest of the Company including fixation of their remuneration and reimbursement of out of pocket expenses incurred in connection hereto."

SPECIAL BUSINESS

4. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

"**RESOLVED THAT,** pursuant to sections 149, 150, 152 and other applicable provisions, if any, of the Companies Act, 2013 and various Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Rules framed there under, read with Schedule IV to the Act (including any statutory modification(s) or re-enactment thereof for the time being in force) **Dr. Subhash Salunke** (DIN:07940567), who was appointed as an Additional Independent Director on October 28, 2017, whose term of office expires at this Annual General Meeting who has submitted a declaration that he meets the criteria for independence as provided in Section 149(6) of the Act and who is eligible for appointment, be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation and to hold office for a term of five consecutive years with effect from September 29, 2018 to September 28, 2023.

RESOLVED FURTHER THAT any Director and/or Company Secretary of the Company be and is hereby authorized severally to do all such acts, deeds, matters and things as may be considered necessary, desirable and expedient for giving effect to this resolution, matters incidental thereto and/or otherwise considered by them to be in the best interest of the Company."

5. To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

RESOLVED THAT, pursuant to sections 149, 150, 152 and other applicable provisions, if any, of the Companies Act, 2013 and various Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Rules framed there under, read with Schedule IV to the Act (including any statutory modification(s) or re-enactment thereof for the time being in force) Dr. Abhay Chowdhary (holding DIN: 02503280) who was appointed as an Additional Non-executive Non- Independent Director on 05th February, 2018 whose term of office expires at this Annual General Meeting who has submitted a declaration that he meets the criteria for independence as provided in Section 149(6) of the Act and who is eligible for appointment, be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation and to hold office for a term of five consecutive years with effect from September 29, 2018 to September 28, 2023.

RESOLVED FURTHER THAT any Director and/or Company Secretary of the Company be and is hereby authorized severally to do all such acts, deeds, matters and things as may be considered necessary, desirable and expedient for giving effect to this resolution, matters incidental thereto and/or otherwise considered by them to be in the best interest of the Company."

6. To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution:

"**RESOLVED THAT** pursuant to Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with the applicable provisions of the Companies Act, 2013 and the rules framed thereunder, including any statutory modification(s) or re-enactment thereof for the time being in force, approval of the Company be and is hereby accorded to the Board of Directors (the "Board"), which term shall include any Committee thereof constituted/ to be constituted by the Board, to enter into such contracts/ arrangements/ transactions with Yashraj Biotechnology Limited, related party of the Company for the purposes of the Companies Act, 2013 and the Listing Regulations, for an amount which may exceed the threshold for material related party transactions, by an amount not exceeding an aggregate value of Rs. 3,00,00,000 (Rupees Three Crores) for the financial Year 2018-19 on such terms and conditions as may be decided by the Board.

RESOLVED FURTHER THAT the Director and Company Secretary hereby authorized to do all such acts, deeds, things and matters and give all such directions as it may in its absolute discretion deem necessary, expedient or desirable, in order to give effect to this resolution."

RESOLVED FURTHER THAT all actions taken by the Board in connection with any matter referred to or contemplated in any of the foregoing resolutions are hereby approved, ratified and confirmed in all respects."

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(FORMERLY KNOWN AS UTKAL SOAP PRODUCTS LIMITED) Sd/-Mamta Mav Company Secretary

Place : Mumbai Dated :-11-08-2018

NOTES FOR MEMBERS:

- 1. A member entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend and vote on poll instead of himself/herself and such proxy need not be a member of the Company.
- 2. Proxies in order to be effective must be received by the Company at the Registered Office of the Company not less than 48 hours before the commencement of the meeting.
- 3. The Register of Members and Share Transfer Books of the Company in respect of Equity Shares will remain closed from **September 27, 2018 to September 29, 2018** (both days inclusive).
- 4. Statement as required under section 102 of the Companies Act, 2013, in respect of special business is annexed hereto.
- 5. M/s. Sharex Dynamics (India) Pvt. Ltd having registered office at Unit-1, Luthra Ind. Premises, Safed pool, Andheri Kurla Road, Andheri (E), Mumbai- 400072 is the Registrar and Share Transfer Agent (STA) of the Company. All communications in respect of share transfers and change in the address of the members may be communicated to them.
- 6. Members holding shares in the same name under different Ledger Folios are requested to apply for consolidation of such Folios and send the relevant share certificates to the Share Transfer Agent/Company.
- 7. Corporate members intend Corporate members intending to send their authorised representatives to attend the meeting are requested to send to the Company a certified copy of the Board resolution authorising their representative to attend and vote on their behalf at the meeting.
- 8. Relevant documents referred to in the accompanying Notice are open for inspection by the members at the Registered office of the Company on all working days, between 11.00 A.M. to 1.00 P.M. upto the date of the meeting.
- 9. Members/Proxies are requested to bring the attendance slip filled in for attending the Meeting.
- 10. Members who hold shares in physical form can nominate a person in respect of all the shares
- 11. held by them singly or jointly. Members who hold shares in single name are advised, in their own interest to avail the nomination facility. Members holding shares in dematerialized form may contact their respective depository participant(s) for recording nomination in respect of their shares.
- 12. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN details to the Company / RTA.

13. E-VOTING

The business as set out in the Notice may be transacted through electronic voting system and the Company is providing facility for voting by electronic means. Pursuant to the provisions of Section 108 of the Companies Act, 2013, read with the Companies (Management and Administration) Rules, 2014, the Company is pleased to offer e-voting facility as an alternate to its members to cast their votes electronically on all resolutions set forth in the Notice convening the 545th Annual General Meeting. The Company has engaged the services of **National Securities Depository Limited** to provide the e-voting facility.

The Members whose names appear in the Register of Members / List of Beneficial Owners as on September 22, 2018 (cut-off date), are entitled to vote on the resolutions set forth in this Notice.

The e-voting period will commence on Wednesday September 26, 2018(09:00 hrs) and will end on Friday, September

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

ANNUAL REPORT 2017-2018

28, 2018 (17:00 hrs). During this period, shareholders of the Company holding shares either in physical form or in dematerialized form, as on the cut-off date may cast their vote electronically. The e-voting module shall be disabled by NSDL for voting thereafter. Members will not be able to cast their votes electronically beyond the date & time mentioned above.

PROCEDURE FOR E-VOTING:

In case a Member receives an email from NSDL [for members whose email IDs are registered with the Company/ Depository Participants(s)] :

- (i) Open email and open PDF file viz; "remote e-voting.pdf" with your Client ID or Folio No. as password. The said PDF file contains your user ID and password/PIN for remote e-voting. Please note that the password is an initial password.
- (ii) Launch internet browser by typing the following URL: https://www.evoting.nsdl.com/
- (iii) Click on Shareholder Login
- (iv) Put user ID and password as initial password/PIN noted in step (i) above. Click Login.
- (v) Password change menu appears. Change the password/PIN with new password of your choice with minimum 8 digits/ characters or combination thereof. Note new password. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (vi) Home page of remote e-voting opens. Click on remote e-voting: Active Voting Cycles.
- (vii) Select "EVEN" of "ASPIRA PATHLAB & DIAGNOSTICS LIMITED (Formerly known as Utkal Soap Products Limited)".
- (viii) Now you are ready for remote e-voting as Cast Vote page opens.
- (ix) Cast your vote by selecting appropriate option and click on "Submit" and also "Confirm" when prompted.
- (x) Upon confirmation, the message "Vote cast successfully" will be displayed.
- (xi) Once you have voted on the resolution, you will not be allowed to modify your vote.
- (xii) Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer through e-mail to pandeysk2004@yahoo.co.in with a copy marked to evoting@nsdl.co.in
- B. In case a Member receives physical copy of the Notice of AGM [for members whose email IDs are not registered with the Company/Depository Participants(s) or requesting physical copy]:
- (i) Initial password is provided as below/at the bottom of the Attendance Slip for the AGM) :

EVEN (Remote e-voting Event Number)	USER ID	PASSWORD/PIN

- (ii) Please follow all steps from SI. No. (ii) to SI. No. (xii) above, to cast vote.
- II. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Members and remote e-voting user manual for Members available at the downloads section of www.evoting.nsdl.com or call on toll free no.: 1800-222- 990.
- III. If you are already registered with NSDL for remote e-voting then you can use your existing user ID and password/PIN for casting your vote.

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

- IV. You can also update your mobile number and e-mail id in the user profile details of the folio which may be used for sending future communication(s).
- V. The voting rights of members shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date of 22nd September 2018.
- VI. Any person, who acquires shares of the Company and become member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e. 31st August, 2018 may obtain the login ID and password by sending a request at evoting@nsdl.co.in.
- VII. However, if you are already registered with NSDL for remote e-voting then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password by using "Forgot User Details/Password" option available on www.evoting.nsdl.com or contact NSDL at the following toll free no.: 1800-222-990.
- VIII. A member may participate in the AGM even after exercising his right to vote through remote e-voting but shall not be allowed to vote again at the AGM.
- IX. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting as well as voting at the AGM through ballot/Poll paper.
- 14. Mr. Santoshkumar .K. Pandey, Practicing Company Secretaries (Membership No. ACS 8546) and/or failing Ms. Sajedabanu Patel or Ms. Pooja Jobanputra an Independent Professional has been appointed as the Scrutinizer to Scrutinize the Evoting process in a fair and transparent manner (including the Ballot/Poll Form received from the members who do not have access to the e-voting process) in a fair and transparent manner.
- 15. The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of "remote e-voting" or "Ballot/Poll Paper" for all those members who are present at the AGM but have not cast their votes by availing the remote e-voting facility.
- 16. The Scrutinizer shall after the conclusion of voting at the general meeting, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than two days of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- 17. The Results declared along with the report of the Scrutinizer shall be placed on the website of the Company www.aspiradiagnostics.com and on the website of NSDL immediately after the declaration of result by the Chairman or a person authorized by him in writing. The results shall also be immediately forwarded to the Calcutta Stock Exchange Limited (CSE) and BSE Limited, Mumbai.
- Subject to receipt of requisite number of votes, the resolutions shall be deemed to be passed on the date of AGM i.e. September 29, 2018.)

EXPLANATORY STATEMENT

(Pursuant to Section 102 of the Companies Act, 2013)

As required by section 102 of the Companies Act, 2013, the following explanatory statements sets out all material facts relating to the business mentioned under Item Nos. 4 ,5 and 6 of the accompanying notics:

Item No. 4

At the Board Meeting of the Company held on October 28, 2017, the Board had appointed Dr. Subhash Salunke as an additional independent director of the Company with immediate effect. In terms of Section 161(1) of the Act, Dr. Subhash Salunke holds office upto the date of this Annual General Meeting and is eligible for appointment as Director.

The appointment of Dr. Subhash Salunke shall be effective upon approval by the members in the Meeting. Dr. Subhash Salunke is not disqualified from being appointed as a Director in terms of Section 164 of the Act and has given her consent to act as a Director of the Company and has given declaration to the Board that he meets criteria for independence as provided under section 149(6) of the Act and Regulation 16 (1)(b) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Brief Resume of Dr. Subhash Salunke

Dr. Subhash Salunke has an MBBS, a Diploma in Public Health, a Diploma in Industrial Health and an M.D. from the University of Pune.

He is the Senior Advisor, Health Systems Support Unit (HSSU), PHFI since 15th May, 2010.

Dr. Subhash Salunke has been an effective and popular faculty in the subject of Preventive and Social Medicine (Community Medicine) for eight years and a postgraduate guide. Also, he was an adjunct Associate professor of Biological Sciences, human ecology at the University of Texas, USA – School of Public Health – from 1994 to 2000. His 30 years' experience in the Public Health Department spans from Deputy Director to Director General in the Health Services of Maharashtra. Most of his illustrative examples of achievements in contemporary Public Health emanate from his own personal experience. Being an achiever, he has experienced a meteoric rise in the field of Public Health. His stint with the WHO SEARO spanned from being Regional Advisor in 2005 to Assistant Regional Director in 2009, including three years as the WHO representative to Indonesia.

He has navigated various portfolios in Public Health not only by fulfilling goals and targets but also by demonstrating innovative and rational ways. He has assisted State Governments to initiate a number of schemes, mainly focusing on health services to the poorer section of society. He was actively involved in formulating projects like "Health System Development" for Maharashtra that was supported by the World Bank. He has shown leadership in designing the HIV/AIDS Control special programme (AVERT) with the assistance of USAID for Maharashtra State. He was one of the members of designing National AIDS Control Programme Phase II during 1999-2000 that was a major step in control of HIV/AIDS through the National Programme for Control of HIV/AIDS.

Accordingly, the Board commends the Ordinary Resolution as set out in item No. 4 of the accompanying notice.

Except Dr. Subhash Salunke, none of the Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financial or otherwise, in the resolution set out at Item No. 4.

Item No. 5

At the Board Meeting of the Company held on February 05, 2018, the Board had appointed Dr. Abhay Chowdhary as an additional director of the Company with immediate effect. In terms of Section 161(1) of the Act, Dr. Abhay Chowdhary holds office upto the date of this Annual General Meeting and is eligible for appointment as Director.

The appointment of Dr. Abhay Chowdhary shall be effective upon approval by the members in the Meeting. Dr. Abhay Chowdhary is not disqualified from being appointed as a Director in terms of Section 164 of the Act and has given her consent to act as a Director.

Brief Resume of Dr. Abhay Chowdhary

Dr. Abhay Chowdhary was Director and Head of Virology & amp; Immunology at the Prestigious Haffkine Institute, Mumbai, India between, April 2008-May 2015. He was the Director of AIDS Research and Control (ARCON) centre, Sir J J hospital, Mumbai during Aug 2005 to Aug 2009. He has an experience of 40 years as a post-graduate teacher in Clinical Microbiology as Professor & amp; Head of Microbiology at Grant Medical College & amp; Sir J J Hospital, Mumbai, and SBH Govt. Medical College, Dhule.

He also serves as an Advisor and Consultant in the field of Laboratory Medicine, HIV/AIDS, Healthcare safety and Quality Management Systems in Clinical Laboratory. He was the Chairman, Board of Studies, Member of Super specialty subjects, Member of Faculty of Medicine and member of Academic Council of MUHS.

He has been an expert team member for Assessment of National Reference Laboratories (NRLs) & amp; State Reference Laboratories (SRLs) under National AIDS Control Organization (NACO), Government of India, along with Expert Teams from CDC, USA and WHO, 2008 – 2010.

He received Fogarty fellowship for Training at Johns Hopkins University, USA in 2003.

Dr Abhay Chowdhary is a Certified Technical Assessor for NABL & amp; NABH. He is the Member of the Standing Committee on Zoonoses, Ministry of Health & amp; Family Welfare, Govt. of India. He serves on editorial boards of International Journal of STD & amp; AIDS & amp; several peer reviewed journals. His expertise and special interests include Medical Virology, Clinical Microbiology, Parasitology, Immunology and Infectious Diseases.

He was Secretary of Indian Association of Medical Microbiologists (IAMM). He was the Secretary of Infectious Diseases Society of India (IDSI). He was President of Indian Association of Medical

Microbiologists(IAMM).

He was awarded with:

- Life Time Achievement Award in Microbiology by Indian Association of Applied Microbiologists 2010
- Presidential Oration Award by Indian Association of Medical Microbiologists, 2010
- Innovations in Science & Technology Award 2011, by SAARC, 2011.
- Dr W.M. Haffkine Oration Award by Hebrew University at Jerusalem, Israel
- Dr H I Jhala Award for outstanding contribution in field of Medical Microbiology by Indian Association of Medical Microbiologists 2012.
- IDMA Research Award 2013, for the best research paper by Indian Drug Manufacturer's Association (IDMA).
- Prof. Dr S Subramaniam Oration Award 2014 awarded for excellence and significant contribution to the field of Medical and Pharmaceutical virology in India by International Association of Medical and Pharmaceutical Virologists.

Accordingly, the Board commends the Ordinary Resolution as set out in item No. 5 of the accompanying notice.

Except Dr. Abhay Chowdhary, none of the Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financial or otherwise, in the resolution set out at Item No. 5.

Item No. 6

Yashraj Biotechnology Limited, is a promoter Company of Aspira Pathlab & Diagnostics Limited (Formerly known as Utkal Soap Products Limited) and is a "Related Party"

Moreover, the estimated value of the transactions relating to ongoing sale, Purchase or receipt of products, goods and materials or availing or rendering of services or taking of loan or leasing of property of any kind (Movable or immovable) with Yashraj Biotechnology Limited during the Financial Year are likely to exceed the threshold prescribed under Regulations 23 of the SEBI (LODR) Regulations 2015 and will be considered material and therefore would require the approval of shareholders of the Company by a Special Resolution.

The particulars of the Contracts/Arrangements/transactions Pursuant to sub-rule (3) of Rule 15 of Companies (Meetings of the Board and its Powers) Rules, 2014 read along with Regulations 23 of SEBI (LODR) Regulations are as follows:

Details required for Omnibus Approval

SR. No.	Particulars	
1.	The name/s of the related Party	Yashraj Biotechnology Limited
2.	Nature of transaction	Rendering and Availing Service
3.	Period of Transaction	One Year
4.	Maximum amount of transaction that can be entered into	Rs. 3,00,00,000 (Rupees Three Crores)
5.	The indicative base price/current contracted price and the formula for variation in the price, if any	Nil
6.	Such other conditions as may deems fit by Board of Directors	


The contracts/ arrangements/ transactions with Yashraj Biotechnology Limited are necessary in the ordinary course and have a significant role in the Company's operations. Therefore, the Board of Directors commends the resolution as set-out at item no. 6 for approval of the shareholders as an Ordinary Resolution.

None of the Directors and Key Managerial Personnel of the Company or their respective relatives is concerned or interested, financially or otherwise, in the resolution set-out at item no. 6 except Mr. Arvind Bhanushali and Dr. Paresh Bhanushali, as they are common director in Company and Yashraj Biotechnology Limited.

Additional Information of Directors recommended for appointment/re-appointment in terms of Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards on General Meeting (SS-2):

Name of Director	Mr. Arvind Bhanushali
Date of birth / Age	20 th April, 1963/ 54 years
Qualification	B.com
Expertise in specific functional areas	Finance, banking, Corporate re-structuring, capital market
Date of appointment on the Board	30/05/2016
Terms and conditions of appointment/ Re-appointment along with details of remuneration sought to be paid and remuneration last drawn by such person	Appointed as executive director, liable to retire by rotation

Directorship held in other Companies	Yash-Raj Diagnostics Pvt. Ltd
	Yashraj Biotechnology Limited
	CFM Advisors Private Limited
	CFM Asset Reconstruction Private Limited
	Aspira Diagnostics Private Limited
	Chartered Finance Management Limited
Chairmanship/Membership in Committees	Chairman of Yashraj Biotechnology Limited
of other Boards	 Member of Audit Committee of Yashraj Biotechnology Limited
Shareholding in the Company	11.27%
Relationship with other Directors KMP of the Company	None
Number of meetings of the Board attended during the	6 of 6
financialyear 2017-18	



ROUTE MAP